

1  
2

3

4

5 **Proposed Project Scope**

6

7

8

9

# Nab-paclitaxel and Gemcitabine for the Adjuvant Treatment of Pancreatic Cancer

10

11

12

13

14

15

16

17

18

19

20

21

22

Date: February 2024

23

## 24 Background and Rationale

25 CADTH received a request from public drug programs for a Non-Sponsored Reimbursement Review of nab-paclitaxel  
26 and gemcitabine for the adjuvant treatment of pancreatic cancer.

### 27 Table I: Policy Questions

Item	Policy Question
1	Should nab-paclitaxel and gemcitabine be publicly reimbursed for adjuvant pancreatic cancer?

28

### 29 Table II: Products Available in Canada

Product	Manufacturer
Nab-paclitaxel	n/a
Gemcitabine	n/a

## 30 Project Description

### 31 Table III: Project Scope

Criteria	Description
Population	Treatment-naïve patients with pancreatic ductal adenocarcinoma with no history of metastatic or locally recurrent disease
Intervention(s)	Nab-paclitaxel/gemcitabine
Comparators	Single agent gemcitabine; gemcitabine/capecitabine; FOLFIRINOX
Outcomes	Overall survival, disease-free survival, adverse events

32

### 33 Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of nab-paclitaxel and gemcitabine for adjuvant pancreatic cancer?
2	What are the harms associated with nab-paclitaxel and gemcitabine for adjuvant pancreatic cancer?
3	What is the expected cost of nab-paclitaxel and gemcitabine for adjuvant pancreatic cancer vs. other reimbursed regimes?

34

35

## 36 Key Project and Protocol Components

37 This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

## 38 Status of the Document

39 This proposed project scope is being posted for information.